Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer|Luminal B
Interventions: DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Durvalumab
Sponsor: Grand Hôpital de Charleroi
Collaborators: Cliniques universitaires Saint-Luc- Université Catholique de Louvain